A study for clinical efficacy and safety of Jianpiwenshen cataplasm preparation and acupoint application in treatment of IBS-D

A study on clinical efficacy and safety of Jianpiwenshen cataplasm preparation and acupoint application in treatment of IBS-D

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IIR-17012250

Enrollment

Unknown

Registered

2017-08-04

Start date

2017-08-01

Completion date

Unknown

Last updated

2017-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IBS-D

Interventions

treatment group:Invigorate the spleen and invigorate the kidney cataplasm

Control Group:placebo cataplasm

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Accord with IBS-D western medicine Rome III diagnostic standard; (2) Accord with TCM syndrome differentiation of spleen kidney yang deficiency syndrome; (3) aged 18 to 65 years old, males or females; (4) informed consent, voluntary test, informed consent process in line with the regulations of GCP.

Exclusion criteria

Exclusion criteria: (1) Infectious diarrhea; (2) Diarrhea caused by systemic diseases, poisoning,and malignant tumor; (3) Complicated with cardio-cerebrovascular, hepatorenal, endocrine, hematopoietic system severe primary disease; (4) Pregnant or lactating women; (5) Allergic constitution; (6) Mental disease, suspected or indeed a history of alcohol or substance abuse; (7) Other lesions that reduce the possibility of grouping or complicate grouping, according to the researcher's judgment; (8) Patients who are participating in other clinical trials of drugs.

Design outcomes

Primary

Measure	Time frame
IBS-BSS;abdominal pain;Stool character;	—

Countries

China

Contacts

Public ContactWang Hong

Shunyi Hospital, Beijing Hospital of TCM

syzyyypwbk@163.com+86 010-89413333

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026